Efzofitimod 1 mg/kg + Efzofitimod 3 mg/kg + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

SARS-CoV-2 (COVID-19) Severe Pneumonia

Conditions

SARS-CoV-2 (COVID-19) Severe Pneumonia

Trial Timeline

Jun 4, 2020 → Oct 23, 2020

NCT ID

NCT04412668

About Efzofitimod 1 mg/kg + Efzofitimod 3 mg/kg + Placebo

Efzofitimod 1 mg/kg + Efzofitimod 3 mg/kg + Placebo is a phase 2 stage product being developed by aTyr Pharma for SARS-CoV-2 (COVID-19) Severe Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT04412668. Target conditions include SARS-CoV-2 (COVID-19) Severe Pneumonia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04412668	Phase 2	Completed	Jun 4, 2020	Oct 23, 2020	SARS-CoV-2 (COVID-19) Severe Pneumonia

Competing Products

20 competing products in SARS-CoV-2 (COVID-19) Severe Pneumonia

See all competitors

Product	Company	Stage	Hype Score
CT-P59	Celltrion	Phase 1	33
CT-P63 + Placebo	Celltrion	Phase 1	33
CT-P59 + CT-P59 + Placebo + CT-P59 + Placebo	Celltrion	Phase 2/3	65
CT-P59 + Placebo	Celltrion	Phase 1	33
S-268019-b + Placebo	Shionogi	Phase 3	77
S-217622 + Placebo	Shionogi	Phase 3	77
S-217622 + Placebo	Shionogi	Phase 3	77
FOY-305 + Placebo	Ono Pharmaceutical	Phase 3	77
Nitric Oxide	Glenmark Pharmaceuticals	Phase 3	77
Mesenchymal stem cell + Placebo	Rohto Pharmaceutical	Phase 2	52
Evusheld	AstraZeneca	Pre-clinical	23
Biological: AZD3152 + Biological: Placebo	AstraZeneca	Phase 2	52
AZD5156 (Parent study Sentinel Safety Cohort) + Placebo (Parent study Sentinel Safety Cohort) + EVUSHELD™ (Parent study Main Cohort) + AZD3152 (Parent study Main Cohort) + Placebo (Parent study Main Cohort) + AZD3152 (Sub-study) + AZD7442 - EVUSHELD™ (Sub-study) + AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152	AstraZeneca	Phase 2/3	65
EVUSHELD	AstraZeneca	Pre-clinical	23
AZD1222	AstraZeneca	Approved	85
AZD3152 (Cohort 1) + Placebo (Cohort 1) + AZD3152 (Cohort 2) + Placebo (Cohort 2) + AZD3152 (Cohort 3) + Placebo (Cohort 3)	AstraZeneca	Phase 1	33
EVUSHELD	AstraZeneca	Pre-clinical	23
AZD7442	AstraZeneca	Phase 1	33
EVUSHELD	AstraZeneca	Pre-clinical	23
Molnupiravir 200 mg + Molnupiravir 400 mg + Molnupiravir 800 mg + Placebo (PBO)	Merck	Phase 2	52

Other Products from aTyr Pharma

efzofitimod 450 mg + efzofitimod 270 mg + PlaceboPhase 2

ATYR1940Phase 1/2

Efzofitimod 1.0 mg/kg or Placebo + Efzofitimod 3.0 mg/kg or Placebo + Efzofitimod 5.0 mg/kg or PlaceboPhase 1/2

ATYR1940 + PlaceboPhase 1/2